Mylan NV (NASDAQ:MYL) saw some unusual options trading on Tuesday. Stock investors acquired 24,068 put options on the stock. This represents an increase of 1,602% compared to the typical volume of 1,414 put options.
MYL has been the subject of a number of research analyst reports. Wells Fargo & Co downgraded Mylan from an “outperform” rating to a “market perform” rating in a report on Tuesday. BidaskClub upgraded Mylan from a “sell” rating to a “hold” rating in a report on Monday. Zacks Investment Research upgraded Mylan from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 30th. Cantor Fitzgerald restated a “hold” rating and set a $41.00 price objective on shares of Mylan in a report on Monday, April 1st. Finally, Argus dropped their price objective on Mylan to $32.00 and set a “buy” rating for the company in a report on Wednesday, March 27th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $39.89.
In other Mylan news, insider Paul Campbell sold 11,533 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $27.50, for a total value of $317,157.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.81% of the company’s stock.
Shares of Mylan stock opened at $21.53 on Wednesday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 0.83. Mylan has a twelve month low of $21.52 and a twelve month high of $42.50. The firm has a market cap of $14.57 billion, a P/E ratio of 4.70, a price-to-earnings-growth ratio of 1.18 and a beta of 1.44.
Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.03. Mylan had a net margin of 3.08% and a return on equity of 19.06%. The firm had revenue of $2.50 billion during the quarter, compared to analysts’ expectations of $2.70 billion. During the same period in the prior year, the company earned $0.96 EPS. The firm’s revenue was down 7.0% on a year-over-year basis. As a group, sell-side analysts expect that Mylan will post 4.38 earnings per share for the current year.
WARNING: “Investors Buy High Volume of Mylan Put Options (MYL)” was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/08/investors-buy-high-volume-of-mylan-put-options-myl.html.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.